Scottish Health Technologies Group, Health Improvement Scotland, 4 May 2018
- Key points
- The quantity and quality of the evidence base was not sufficient to determine the diagnostic accuracy of 18F-fluorodeoxyglucose (FDG) PET/CT in the context of investigating patients with suspected myeloma.
- In the assessment of newly-diagnosed myeloma patients, there was evidence that FDG PET/CT is likely to detect more lesions than x-ray, but when compared to other modern imaging methods (MRI being the most commonly used comparator) there was conflicting evidence about whether FDG PET/CT can detect more lesions.
- There is evidence that FDG PET/CT is not cost-effective for the diagnosis of myeloma across a wide range of sensitivity and specificity values (60-100%).
- No relevant cost-effectiveness studies were identified to assess the cost-effectiveness of FDG PET/CT among newly-diagnosed myeloma populations.
